Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

Characteristics and clinical outcomes of newly diagnosed acute myeloid leukemia with MAPK pathway mutations: A referral-center retrospective analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKensuke TakaokaSMSarah L. MottRYRatdanai Yodsuwan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows MAPK mutations impact survival in adults with newly diagnosed acute myeloid leukemia, suggesting treatment considerations.

Key Points

  • This analysis aims to characterize clinical outcomes of acute myeloid leukemia patients with MAPK pathway mutations.
  • Retrospective analysis of adult patients with newly diagnosed acute myeloid leukemia at University of Iowa (N=74), March 2015 to December 2024.
  • Evaluated overall survival and composite complete remission rates; used logistic regression and Cox regression for analysis.
  • Patients treated with intensive (anthracycline-based) or non-intensive (hypomethylating agents) induction regimens.
  • Median overall survival was 58.7 months for intensive regimens and 7.5 months for non-intensive; 0.2 months for untreated patients.
  • KRAS mutations increased hazard for poor overall survival (HR: 2.14, 95% CI: 1.10-4.17) and abnormal karyotype decreased odds for achieving complete remission (OR: 0.25, 95% CI: 0.07-0.89).
  • 53% overall composite complete remission rate observed with age impacting treatment outcomes significantly.

Cite This Study

Takaoka et al. (2026) studied this question.

synapsesocial.com/papers/6a1a7f760307b78509431bd5https://doi.org/10.1200/jco.2026.44.16_suppl.e18506
View Full Paper
Ask AI
Bookmark
Share